Manipal Hospitals to Acquire Sahyadri for ₹6,400 Cr in Major Healthcare Deal

New Delhi — In a major development in India’s private healthcare landscape, Manipal Hospitals has sought approval from the Competition Commission of India (CCI) to acquire Sahyadri Hospitals, a leading Western India-based hospital chain, for a reported ₹6,400 crore.

This strategic move is expected to bolster Manipal’s footprint in Maharashtra and consolidate its position as one of the top three hospital networks in the country by bed capacity and revenue.

🏥 Sahyadri’s Presence:

Sahyadri Hospitals operates nine multi-speciality hospitals across cities like Pune, Nashik, and Karad, with a total bed strength of over 900 beds. The chain is known for its strong clinical specialties in oncology, neurology, cardiology, and organ transplants.

💼 Strategic Push by Manipal:

Manipal Hospitals, backed by global investment firm TPG Capital, has been actively expanding. The group previously acquired Columbia Asia and Vikram Hospital, building one of India’s largest integrated health networks.

This latest deal signals continued consolidation in India’s private healthcare market, driven by the rising demand for quality tertiary care, operational synergies, and access to underserved regional hubs.

🔍 What Comes Next:

The acquisition plan now awaits CCI’s approval, which is a mandatory regulatory step to ensure compliance with India’s antitrust laws. If cleared, the integration is likely to enhance patient access to Manipal’s standardised protocols, advanced medical tech, and streamlined care delivery across Western India.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre